Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Irritable Bowel Syndrome, March 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 99 articles:
HTML format


 

Single Articles

  1. HAN CJ, Kohen R, Jun S, Jarrett ME, et al
    COMT Val158Met Polymorphism and Symptom Improvement Following a Cognitively Focused Intervention for Irritable Bowel Syndrome.
    Nurs Res. 2017;66:75-84.
    Abstract    

    Abstract available

  2. DE PALMA G, Lynch MD, Lu J, Dang VT, et al
    Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice.
    Sci Transl Med. 2017;9.
    Abstract    

    Abstract available

  3. LOWE C, Aiken A, Day AG, Depew W, et al
    Sham acupuncture is as efficacious as true acupuncture for the treatment of IBS: A randomized placebo controlled trial.
    Neurogastroenterol Motil. 2017 Mar 2. doi: 10.1111/nmo.13040.
    Abstract    

    Abstract available

  4. SUGAWARA N, Sato K, Takahashi I, Satake R, et al
    Depressive Symptoms and Coping Behaviors among Individuals with Irritable Bowel Syndrome in Japan.
    Intern Med. 2017;56:493-498.
    Abstract    

    Abstract available

  5. DLUGOSZ A, Zakikhany K, Acevedo N, D'Amato M, et al
    Increased Expression of Toll-Like Receptors 4, 5, and 9 in Small Bowel Mucosa from Patients with Irritable Bowel Syndrome.
    Biomed Res Int. 2017;2017:9624702.
    Abstract    

    Abstract available

  6. CLAVE P, Tack J
    Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis.
    Therap Adv Gastroenterol. 2017;10:311-322.
    Abstract    

    Abstract available

  7. MOSER G, Peter J
    [Brain-gut axis and gut-directed hypnosis - success of an integrated psychosomatic treatment in gastroenterology].
    Z Psychosom Med Psychother. 2017;63:5-19.
    Abstract    



  8. ASHRAFI-ASGARABAD A, Ayubi E, Safiri S
    Prevalence and impact of irritable bowel syndrome in people with epilepsy: Methodological issues.
    Epilepsy Behav. 2017 Feb 24. pii: S1525-5050(16)30648.
    Abstract    



  9. MULUGETA M, Tache Y, Larauche M, Yuan PQ, et al
    Brain and gut CRF signaling: biological actions and role in the gastrointestinal tract.
    Curr Mol Pharmacol. 2017 Feb 23. doi: 10.2174/1874467210666170224095741.
    Abstract    

    Abstract available

  10. SANCHEZ CUEN JA, Irineo Cabrales AB, Bernal Magana G, Peraza Garay FJ, et al
    Health-related quality of life in adults with irritable bowel syndrome in a Mexican specialist hospital. A cross-sectional study.
    Rev Esp Enferm Dig. 2017;109.
    Abstract    

    Abstract available

  11. MEARIN F, Ciriza C, Minguez M, Rey E, et al
    [Irritable bowel syndrome with constipation and functional constipation in adults: Treatment (Part 2 of 2)].
    Aten Primaria. 2017 Feb 23. pii: S0212-6567(17)30131.
    Abstract    

    Abstract available

  12. YI L, Zhang H, Sun H, Zhou L, et al
    Maternal Separation Induced Visceral Hypersensitivity from Childhood to Adulthood.
    J Neurogastroenterol Motil. 2017 Feb 25. doi: 10.5056/jnm16089.
    Abstract    

    Abstract available

  13. BEATTY JK, Akierman SV, Motta JP, Muise S, et al
    Giardia duodenalis induces dysbiosis of human intestinal microbiota biofilms.
    Int J Parasitol. 2017 Feb 22. pii: S0020-7519(17)30040.
    Abstract    

    Abstract available

  14. KUMAR S, Shukla R, Ranjan P, Kumar A, et al
    Interleukin-10: A Compelling Therapeutic Target in Patients With Irritable Bowel Syndrome.
    Clin Ther. 2017 Feb 23. pii: S0149-2918(17)30076.
    Abstract    

    Abstract available

  15. SAPS M, Miranda A
    Gastrointestinal Pharmacology.
    Handb Exp Pharmacol. 2017 Feb 25. doi: 10.1007/164_2016.
    Abstract    

    Abstract available

  16. O'MAHONY SM, Clarke G, Dinan TG, Cryan JF, et al
    Irritable Bowel Syndrome and Stress-Related Psychiatric Co-morbidities: Focus on Early Life Stress.
    Handb Exp Pharmacol. 2017 Feb 24. doi: 10.1007/164_2016.
    Abstract    

    Abstract available

  17. PRUSATOR DK, Chang L
    Sex-Related Differences in GI Disorders.
    Handb Exp Pharmacol. 2017 Feb 24. doi: 10.1007/164_2016.
    Abstract    

    Abstract available

  18. KHAN I, Samson SE, Grover AK
    Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal.
    Med Princ Pract. 2017 Mar 8. doi: 10.1159/000468988.
    Abstract    

    Abstract available

  19. CHEN JD, Yin J, Wei W
    Electrical therapies for gastrointestinal motility disorders.
    Expert Rev Gastroenterol Hepatol. 2017 Mar 6. doi: 10.1080/17474124.2017.1298441
    Abstract    

    Abstract available

  20. WHITEHEAD WE, Palsson OS, Simren M
    Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management?
    Expert Rev Gastroenterol Hepatol. 2017.
    Abstract    



  21. CORSETTI M, Whorwell P
    New therapeutic options for IBS: the role of the first in class mixed micro- opioid receptor agonist and delta-opioid receptor antagonist (mudelta) eluxadoline.
    Expert Rev Gastroenterol Hepatol. 2017.
    Abstract    

    Abstract available

  22. LUNA RA, Oezguen N, Balderas M, Venkatachalam A, et al
    Distinct Microbiome-Neuroimmune Signatures Correlate With Functional Abdominal Pain in Children With Autism Spectrum Disorder.
    Cell Mol Gastroenterol Hepatol. 2016;3:218-230.
    Abstract    

    Abstract available

  23. MAILHE M, Ricaboni D, Benezech A, Lagier JC, et al
    'Tidjanibacter massiliensis' gen. nov., sp. nov., a new bacterial species isolated from human colon.
    New Microbes New Infect. 2016;17:21-22.
    Abstract    

    Abstract available

  24. DANTOFT TM, Ebstrup JF, Linneberg A, Skovbjerg S, et al
    Cohort description: The Danish study of Functional Disorders.
    Clin Epidemiol. 2017;9:127-139.
    Abstract    

    Abstract available

  25. VALENTIN N, Camilleri M, Carlson P, Harrington SC, et al
    Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome.
    Physiol Rep. 2017;5.
    Abstract    

    Abstract available

  26. SCHMULSON MJ, Drossman DA
    What is new in Rome IV.
    J Neurogastroenterol Motil. 2017 Mar 9. doi: 10.5056/jnm16214.
    Abstract    

    Abstract available

  27. GHOSHAL UC, Shukla R, Ghoshal U
    Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy.
    Gut Liver. 2017;11:196-208.
    Abstract    

    Abstract available

  28. BANIASADI N, Dehesh MM, Mohebbi E, Hayatbakhsh Abbasi M, et al
    ASSESSING THE SLEEP QUALITY AND DEPRESSION-ANXIETY-STRESS IN IRRITABLE BOWEL SYNDROME PATIENTS.
    Arq Gastroenterol. 2017 Feb 23:0. doi: 10.1590/S0004-2803.201700000.
    Abstract    

    Abstract available

  29. ZENTILIN P, Marabotto E, Pellegatta G, Coppo C, et al
    Complexity and diversity of GERD phenotypes.
    Minerva Gastroenterol Dietol. 2017 Mar 7. doi: 10.23736/S1121-421X.17.02399.
    Abstract    

    Abstract available

  30. HOD K, Sperber AD, Ron Y, Boaz M, et al
    A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS.
    Neurogastroenterol Motil. 2017 Mar 8. doi: 10.1111/nmo.13037.
    Abstract    

    Abstract available

  31. TSE Y, Armstrong D, Andrews CN, Bitton A, et al
    Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents.
    Can J Gastroenterol Hepatol. 2017;2017:8612189.
    Abstract    

    Abstract available

  32. SPIERLING SR, Zorrilla EP
    Don't stress about CRF: assessing the translational failures of CRF1antagonists.
    Psychopharmacology (Berl). 2017 Mar 7. doi: 10.1007/s00213-017-4556.
    Abstract    

    Abstract available

  33. MAO Q, Shi L, Wang ZG, Luo YH, et al
    Chemical profiles and pharmacological activities of Chang-Kang-Fang, a multi-herb Chinese medicinal formula, for treating irritable bowel syndrome.
    J Ethnopharmacol. 2017 Mar 2. pii: S0378-8741(17)30814.
    Abstract    

    Abstract available

  34. BOADAS-VAELLO P, Homs J, Reina F, Carrera A, et al
    Neuroplasticity of Supraspinal Structures Associated with Pathological Pain.
    Anat Rec (Hoboken). 2017 Mar 6. doi: 10.1002/ar.23587.
    Abstract    

    Abstract available

  35. DE BORTOLI N, Natali V, Melissari S, Simonetti N, et al
    Overlap of GERD and gastrointestinal functional disorders.
    Minerva Gastroenterol Dietol. 2017 Mar 3. doi: 10.23736/S1121-421X.17.02398.
    Abstract    

    Abstract available

  36. ARROUK R, Karpinski A, Lavenbarg T, Belmont J, et al
    Water Load Test in Children with Chronic Abdominal Pain or Obesity Compared with Nonobese Controls.
    South Med J. 2017;110:168-171.
    Abstract    

    Abstract available

  37. AZIZ I, Tornblom H, Simren M
    Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty?
    Curr Opin Gastroenterol. 2017 Mar 2. doi: 10.1097/MOG.0000000000000348.
    Abstract    

    Abstract available

  38. ANASTASI JK, Capili B, Chang M
    Development of Acupuncture and Moxibustion Protocol in a Clinical Trial for Irritable Bowel Syndrome.
    J Acupunct Meridian Stud. 2017;10:62-66.
    Abstract    

    Abstract available

  39. LE DH
    Microbiome R&D and Business Collaboration Forum, April 11-12, 2016, London, UK.
    EBioMedicine. 2016;7:2-3.
    Abstract    



  40. ZHANG NZ, Ma L, Jun C, Guo YX, et al
    Changes in mast cell infiltration: a possible mechanism in detrusor overactivity induced by visceral hypersensitivity.
    Int Braz J Urol. 2016;42:373-82.
    Abstract    

    Abstract available

  41. GROSJEAN D, Benini P, Carayon P
    Managing irritable bowel syndrome: The impact of micro-physiotherapy.
    J Complement Integr Med. 2017.
    Abstract    

    Abstract available

  42. TACK J, Drossman DA
    What's new in Rome IV?
    Neurogastroenterol Motil. 2017 Mar 17. doi: 10.1111/nmo.13053.
    Abstract    

    Abstract available

  43. MOORE JS, Gibson PR, Perry RE, Burgell RE, et al
    Endometriosis in patients with irritable bowel syndrome: Specific symptomatic and demographic profile, and response to the low FODMAP diet.
    Aust N Z J Obstet Gynaecol. 2017 Mar 17. doi: 10.1111/ajo.12594.
    Abstract    

    Abstract available

  44. JOHANSSON S, Rosenbaum DP, Ahlqvist M, Rollison H, et al
    Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.
    Clin Pharmacol Drug Dev. 2017 Mar 16. doi: 10.1002.
    Abstract    

    Abstract available

  45. CATASSI G, Lionetti E, Gatti S, Catassi C, et al
    The Low FODMAP Diet: Many Question Marks for a Catchy Acronym.
    Nutrients. 2017;9.
    Abstract    

    Abstract available

  46. HATTAY P, Prusator DK, Tran L, Greenwood-Van Meerveld B, et al
    Psychological stress-induced colonic barrier dysfunction: Role of immune-mediated mechanisms.
    Neurogastroenterol Motil. 2017 Mar 16. doi: 10.1111/nmo.13043.
    Abstract    

    Abstract available

  47. DOIRON PR, du P Menage H, Freeman A, Muneer A, et al
    Peri-meatal PeIN and urethral SCC: a case report.
    J Eur Acad Dermatol Venereol. 2017 Mar 10. doi: 10.1111/jdv.14207.
    Abstract    

    Abstract available

  48. CHEN A, Chen Y, Tang Y, Bao C, et al
    Hippocampal AMPARs involve the central sensitization of rats with irritable bowel syndrome.
    Brain Behav. 2017;7:e00650.
    Abstract    

    Abstract available

  49. IDA M, Nishida A, Akiho H, Nakashima Y, et al
    Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea.
    Biopsychosoc Med. 2017;11:7.
    Abstract    

    Abstract available

  50. PRISCO V, Iannaccone T
    [Inflammatory bowel disease and quality of life: psychopathological variants.]
    Recenti Prog Med. 2017;108:83-89.
    Abstract    

    Abstract available

  51. WILPART K, Tornblom H, Svedlund J, Tack JF, et al
    'Coping Skills are Associated With Gastrointestinal Symptom Severity and Somatization in Patients With Irritable Bowel Syndrome'.
    Clin Gastroenterol Hepatol. 2017 Mar 7. pii: S1542-3565(17)30263.
    Abstract    

    Abstract available

  52. OHLSSON B, Orho-Melander M, Nilsson PM
    Higher Levels of Serum Zonulin May Rather Be Associated with Increased Risk of Obesity and Hyperlipidemia, Than with Gastrointestinal Symptoms or Disease Manifestations.
    Int J Mol Sci. 2017;18.
    Abstract    

    Abstract available

  53. BAILEY C, Ruaux C, Stang BV, Valentine BA, et al
    Expression of serotonin, chromogranin-A, serotonin receptor-2B, tryptophan hydroxylase-1, and serotonin reuptake transporter in the intestine of dogs with chronic enteropathy.
    J Vet Diagn Invest. 2016;28:271-8.
    Abstract    

    Abstract available

  54. NEWLOVE-DELGADO TV, Martin AE, Abbott RA, Bethel A, et al
    Dietary interventions for recurrent abdominal pain in childhood.
    Cochrane Database Syst Rev. 2017;3:CD010972.
    Abstract    

    Abstract available

  55. BLONSKA A, Konrad P, Chojnacki J, Chojnacki C, et al
    [Evaluation of oro-cecal transit time in patients with irritable bowel syndrome with cereal products intolerance].
    Pol Merkur Lekarski. 2017;42:116-120.
    Abstract    

    Abstract available

  56. SCANZI F, Andreoli L, Martinelli M, Taraborelli M, et al
    Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures.
    Immunol Res. 2017 Mar 22. doi: 10.1007/s12026-017-8912.
    Abstract    

    Abstract available

  57. IDA M, Nishida A, Akiho H, Nakashima Y, et al
    Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea.
    Biopsychosoc Med. 2017;11:8.
    Abstract    

    Abstract available

  58. MA X, Wang X, Kang N, Chen T, et al
    The Effect of Tong-Xie-Yao-Fang on Intestinal Mucosal Mast Cells in Postinfectious Irritable Bowel Syndrome Rats.
    Evid Based Complement Alternat Med. 2017;2017:9086034.
    Abstract    

    Abstract available

  59. NAKAO JH, Collier SA, Gargano JW
    Giardiasis and Subsequent Irritable Bowel Syndrome: A Longitudinal Cohort Study Using Health Insurance Data.
    J Infect Dis. 2017 Feb 23. doi: 10.1093.
    Abstract    

    Abstract available

  60. BOWERS H, Wroe A, Pincus T
    The relationship between beliefs about emotions and quality of life in irritable bowel syndrome.
    Psychol Health Med. 2017 Mar 22:1-7. doi: 10.1080/13548506.2017.1307996.
    Abstract    

    Abstract available

  61. SHERWIN LB, Leary E, Henderson WA
    The association of catastrophizing with quality-of-life outcomes in patients with irritable bowel syndrome.
    Qual Life Res. 2017 Mar 21. doi: 10.1007/s11136-017-1554.
    Abstract    

    Abstract available

  62. TOUW K, Ringus DL, Hubert N, Wang Y, et al
    Mutual reinforcement of pathophysiological host-microbe interactions in intestinal stasis models.
    Physiol Rep. 2017;5.
    Abstract    

    Abstract available

  63. PARK A, Conway M
    Longitudinal Changes in Psychological States in Online Health Community Members: Understanding the Long-Term Effects of Participating in an Online Depression Community.
    J Med Internet Res. 2017;19:e71.
    Abstract    

    Abstract available

  64. AL-MOZANY N, Wright C, O'Grady G, Young CJ, et al
    Barriers to the management of obstructed defecation according to colorectal surgeons.
    Colorectal Dis. 2017 Mar 20. doi: 10.1111/codi.13665.
    Abstract    

    Abstract available

  65. MOHAMMADI M, Tahmasebi Abdar H, Mollaei HR, Hajghani H, et al
    Serotonin Transporter Gene (SLC6A4) Polymorphism and Mucosal Serotonin Levels in Southeastern Iranian Patients with Irritable Bowel Syndrome.
    Middle East J Dig Dis. 2017;9:26-32.
    Abstract    

    Abstract available

  66. GHADIR MR, Poradineh M, Sotodeh M, Ansari R, et al
    Mesalazine Has No Effect on Mucosal Immune Biomarkers in Patients with Diarrhea-Dominant Irritable Bowel Syndrome Referred to Shariati Hospital: A Randomized Double-Blind, Placebo-Controlled Trial.
    Middle East J Dig Dis. 2017;9:20-25.
    Abstract    

    Abstract available

  67. MANCEAU H, Chicha-Cattoir V, Puy H, Peoc'h K, et al
    Fecal calprotectin in inflammatory bowel diseases: update and perspectives.
    Clin Chem Lab Med. 2017;55:474-483.
    Abstract    

    Abstract available

  68. WHITEHEAD WE, Duffy K, Sharpe J, Nabata T, et al
    Editorial: ONO-2952 in irritable bowel syndrome with diarrhoea - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1005.
    Abstract    



  69. NEE J, Lembo A
    Editorial: ONO-2952 in irritable bowel syndrome with diarrhoea.
    Aliment Pharmacol Ther. 2017;45:1004-1005.
    Abstract    



  70. STAUDACHER HM, Cox SR
    Editorial: metabolic adaptation of colonic microbiota to galactooligosaccharides - good news for prebiotics in irritable bowel syndrome?
    Aliment Pharmacol Ther. 2017;45:1005-1006.
    Abstract    



  71. CHEY WD, Dove LS, Andrae DA, Covington PS, et al
    Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.
    Aliment Pharmacol Ther. 2017 Mar 22. doi: 10.1111/apt.14031.
    Abstract    

    Abstract available

  72. KARUPPIAH S, Pomianowski K
    Rifaximin (Xifaxan) for Irritable Bowel Syndrome.
    Am Fam Physician. 2017;95:258-259.
    Abstract    



  73. CHEY WD, Lembo AJ, Rosenbaum DP
    Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
    Am J Gastroenterol. 2017 Feb 28. doi: 10.1038/ajg.2017.
    Abstract    

    Abstract available

  74. PETERS SA, Edogawa S, Sundt WJ, Dyer RB, et al
    Constipation-Predominant Irritable Bowel Syndrome Females Have Normal Colonic Barrier and Secretory Function.
    Am J Gastroenterol. 2017 Mar 21. doi: 10.1038/ajg.2017.
    Abstract    

    Abstract available

  75. JOYCE SA, Gahan CG
    Disease-Associated Changes in Bile Acid Profiles and Links to Altered Gut Microbiota.
    Dig Dis. 2017;35:169-177.
    Abstract    

    Abstract available

  76. AL-SALAMA ZT, Syed YY
    Plecanatide: First Global Approval.
    Drugs. 2017 Mar 3. doi: 10.1007/s40265-017-0718.
    Abstract    

    Abstract available

  77. QUIGLEY EM, Lembo AJ
    Irritable Bowel Syndrome: An Infectious Disease?
    Gastroenterology. 2017 Mar 1. pii: S0016-5085(17)30215.
    Abstract    



  78. CAMILLERI M, Boeckxstaens G
    Dietary and pharmacological treatment of abdominal pain in IBS.
    Gut. 2017 Feb 23. pii: gutjnl-2016-313425. doi: 10.1136/gutjnl-2016-313425.
    Abstract    

    Abstract available

  79. AN S, Zong G, Wang Z, Shi J, et al
    Activation of protease-activated receptor 4 of mast cells could downregulate proinflammatory cytokines in irritable bowel syndrome.
    Gut. 2017 Mar 8. pii: gutjnl-2016-313504. doi: 10.1136/gutjnl-2016-313504.
    Abstract    



  80. DE WINTER BY
    Identification of an epithelial member of the protease family, supporting the potential diagnostic and therapeutic role of serine proteases in IBS.
    Gut. 2017 Mar 10. pii: gutjnl-2016-313664. doi: 10.1136/gutjnl-2016-313664.
    Abstract    



  81. GIBSON PR
    Use of the low-FODMAP diet in inflammatory bowel disease.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:40-42.
    Abstract    

    Abstract available

  82. ANKERSEN DV, Carlsen K, Marker D, Munkholm P, et al
    Using eHealth strategies in delivering dietary and other therapies in patients with irritable bowel syndrome and inflammatory bowel disease.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:27-31.
    Abstract    

    Abstract available

  83. IACOVOU M
    Adapting the low FODMAP diet to special populations: infants and children.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:43-45.
    Abstract    

    Abstract available

  84. GIBSON PR
    History of the low FODMAP diet.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:5-7.
    Abstract    

    Abstract available

  85. WILSON B, Whelan K
    Prebiotic inulin-type fructans and galacto-oligosaccharides: definition, specificity, function, and application in gastrointestinal disorders.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:64-68.
    Abstract    

    Abstract available

  86. TAN VP
    The low-FODMAP diet in the management of functional dyspepsia in East and Southeast Asia.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:46-52.
    Abstract    

    Abstract available

  87. BARRETT JS
    How to institute the low-FODMAP diet.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:8-10.
    Abstract    

    Abstract available

  88. GIBSON PR
    The evidence base for efficacy of the low FODMAP diet in irritable bowel syndrome: is it ready for prime time as a first-line therapy?
    J Gastroenterol Hepatol. 2017;32 Suppl 1:32-35.
    Abstract    

    Abstract available

  89. GIBSON PR, Skodje GI, Lundin KE
    Non-coeliac gluten sensitivity.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:86-89.
    Abstract    

    Abstract available

  90. HALMOS EP
    When the low FODMAP diet does not work.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:69-72.
    Abstract    

    Abstract available

  91. VARNEY J, Barrett J, Scarlata K, Catsos P, et al
    FODMAPs: food composition, defining cutoff values and international application.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:53-61.
    Abstract    

    Abstract available

  92. TUCK C, Barrett J
    Re-challenging FODMAPs: the low FODMAP diet phase two.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:11-15.
    Abstract    

    Abstract available

  93. O'KEEFFE M, Lomer MC
    Who should deliver the low FODMAP diet and what educational methods are optimal: a review.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:23-26.
    Abstract    

    Abstract available

  94. MALAKAR S
    Bioactive food chemicals and gastrointestinal symptoms: a focus of salicylates.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:73-77.
    Abstract    

    Abstract available

  95. MEANCE S, Giordano J, Chuang E, Schneider H, et al
    Food regulations: low FODMAP labeling and communication goals.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:62-63.
    Abstract    

    Abstract available

  96. STAUDACHER HM
    Nutritional, microbiological and psychosocial implications of the low FODMAP diet.
    J Gastroenterol Hepatol. 2017;32 Suppl 1:16-19.
    Abstract    

    Abstract available

  97. SAHOO S, Padhy SK
    Cross-cultural and Psychological issues in Irritable Bowel Syndrome.
    J Gastroenterol Hepatol. 2017 Feb 27. doi: 10.1111/jgh.13773.
    Abstract    

    Abstract available

  98. NWOSU BU, Maranda L, Candela N
    Correction: Vitamin D status in pediatric irritable bowel syndrome.
    PLoS One. 2017;12:e0173779.
    Abstract    

    Abstract available

  99. ZHENG Y, Yu T, Tang Y, Xiong W, et al
    Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.
    PLoS One. 2017;12:e0172846.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Irritable Bowel Syndrome is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;